BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36208252)

  • 1. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
    Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li ZY; Li ZJ; Chen X; Huang XR; Fang ZQ; Zhang JG; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1690-1695. PubMed ID: 29262899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li YP; Zhang JG; Fang ZQ; Huang XR; Chen X; Li ZJ; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):482-488. PubMed ID: 30998158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
    Wang L; Cao J; Tao J; Liang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
    Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
    Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
    Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
    Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
    Ge QF; Ouyang GF; Chen Y; Zhang Y; Mu QT; Lu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):112-5. PubMed ID: 22391178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Glutaminolysis to Treat Multiple Myeloma: An
    Li C; Feng Y; Wang W; Xu L; Zhang M; Yao Y; Wu X; Zhang Q; Huang W; Wang X; Li X; Ying P; Shang L
    Anticancer Agents Med Chem; 2023; 23(7):779-785. PubMed ID: 36065917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 11. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Activity of Asiaticoside Against Multiple Myeloma Drug-Resistant Cancer Cells Is Mediated by Autophagy Induction, Activation of Effector Caspases, and Inhibition of Cell Migration, Invasion, and STAT-3 Signaling Pathway.
    Yingchun L; Huihan W; Rong Z; Guojun Z; Ying Y; Zhuogang L
    Med Sci Monit; 2019 Feb; 25():1355-1361. PubMed ID: 30785126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.
    Bao L; Wang Y; Lu M; Shi L; Chu B; Gao S
    Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130299. PubMed ID: 36565997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
    Tang JX; Chen Q; Li Q; He YH; Xiao D
    Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
    Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
    Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
    [No Abstract]   [Full Text] [Related]  

  • 17. Platycodin D inhibits proliferation, migration and induces chemosensitization through inactivation of the NF-κB and JAK2/STAT3 pathways in multiple myeloma cells.
    Wu D; Zhang W; Chen Y; Ma H; Wang M
    Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1194-1200. PubMed ID: 31347196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arsenic trioxide enhances the effects of bortezomib, dexamethasone on multiple myeloma cell line KM3 in vitro.].
    Ouyang GF; Lin MF
    Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):240-3. PubMed ID: 20510040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Curcumin Increases the Chemosensitivity of Multiple Myeloma to Bortezomib by Inhibiting the Notch1 Signaling Pathway].
    Ge XP; Hong YT; Li YL; Li BZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):464-471. PubMed ID: 30998155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.